ClinicalTrials.gg
Active, not recruitingNCT06489847SPPB++Updated Apr 29, 2026

An Objective Assessment Tool for Evaluating Functioning in Older Adults

An observational study in Alzheimer Disease, sponsored by Stanford University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Stanford University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Alzheimer Disease by Stanford University — 2 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Stanford University.

Started
2024
with 1 other
Observational
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Alzheimer Disease by Stanford University, this one is one of 2 that started in 2024, is one of 2 observational ones, and was the 7th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 10 studies in Alzheimer Disease by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alzheimer Disease by Stanford University, or all of them as a file.
02

Study summary

The Investigators are seeking your consent to participate in research investigating the development of a mobile application that enhances physical and cognitive assessments.

This is in response to the growing significance of the Short Physical Performance Battery (SPPB) in Alzheimer's Disease and Related Dementias (AD/ADRD) research. The SPPB has proven its value in evaluating lower extremity function and mobility in older adults, providing predictive insights into declines in daily living activities, falls, hospitalization, disability, and mortality.

Recognizing the need for accessible and automated assessment tools, this project endeavors to design a mobile app with multi-fold functionality. The final version will guide users through SPPB tests, offer real-time performance scoring, and facilitate frequent, objective, and accurate physical and cognitive assessments. This is particularly critical for monitoring the progression of ADRD, identifying subtle physical changes indicative of cognitive decline, and enabling timely interventions tailored to patients' evolving needs.

Our goal is to collect video data from 20 to 30 participants 18+ years of age who are considered healthy with no severe mobility issues to perform the SPPB. The video data will be used to develop a prototype of the SPPB application and validate testing in the lab. The video recording will be automatically encrypted and securely uploaded to Stanford privacy protected computer servers to test and refine the application results.

Read the detailed description

In response to the growing significance of the Short Physical Performance Battery (SPPB) in Alzheimer's Disease and Related Dementias (AD/ADRD) research, this project aims to create a mobile application that enhances physical and cognitive assessments. The SPPB has proven its value in evaluating lower extremity function and mobility in older adults, providing predictive insights into declines in daily living activities, falls, hospitalization, disability, and mortality. Moreover, recent research has revealed the potential of SPPB in detecting cognitive decline through gait and hand movement analysis at various stages of AD and Mild Cognitive Impairment (MCI). Recognizing the need for accessible and automated assessment tools, this project endeavors to design a mobile app with multi-fold functionality. It will guide users through SPPB tests, offer real-time performance scoring, and facilitate frequent, objective, and accurate physical and cognitive assessments. This is particularly critical for monitoring the progression of ADRD, identifying subtle physical changes indicative of cognitive decline, and enabling timely interventions tailored to patients' evolving needs.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer's Disease
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy Adults

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (18+)
  • proficient in English
  • consider themselves healthy
  • Ability to participate in a meeting for consenting and video data collection on Stanford campus

Exclusion criteria

Exclusion Criteria:

  • We will exclude participant that do not consent to video data collection
  • Under the age of 18
  • limited physical mobility.

We have no exclusions on the basis of gender or ethnic background.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testSPPB++ Application

    Participants will have video data collected as they perform the SPPB test one time.

06

What researchers measure

Primary outcomes

  1. develop an automated analysis of the SPPB clinical tests

    Novel Biomarker Types: In this study, we propose to leverage video data to develop an automated analysis of the SPPB clinical tests, the same way that MRI data can automatically be analyzed. This will remove the need for subjective evaluation and lead to universally acceptable disease (digital) biomarkers from the video data, helping the clinicians. The video-based biomarkers will serve as quantifiable identifiers singling out specific subtype(s). Such digital biomarkers \[9-19,21\] and especially video \[20\] are transforming the development of drugs. Video, as a rich source of data, can provide novel information yet to be explored.

    Time frame: 1 year

  2. large-scale data collection to continuously collect data for understanding NPS disease trajectories

    Novel Methodologies: Processing unconstrained video data collected in clinical settings with limited data points calls for new technologies. Although we use recent video recognition technologies (including those developed by us recently), applying them to clinical data and training new machine learning models poses unique challenges requiring novel methods. In addition, implementing this on mobile phones will facilitate the platforms required for large-scale data collection to continuously collect data for understanding disease trajectories.

    Time frame: 1 year

  3. SPPB++ mobile phone app

    Impact: We will implement our novel algorithms in a mobile phone app, making the tests accessible and affordable to many individuals. This will enable large-scale data collection and clinical trials. The analysis of this data will identify novel biomarkers using video-based SPPB tests. The longitudinal assessment of these tests will provide a means for tracking cognitive functioning and convergence to MCI, AD, or other dementia.

    Time frame: 1 year

07

Study locations

1 site
  • Clinical Excellence Research Center
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Oct 2027, 38 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 38 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 8, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 30, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06489847
Responsible party
Ehsan Adeli (Professor, Stanford University) — Principal investigator
First posted
Jul 8, 2024
Start date
Aug 1, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Ehsan Adeli, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion